Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen

Cancer Genetics and Cytogenetics

Volumn 166, Issue 2, 2006, Pages 130-138

  Coutinho Camillo, Cláudia M ^a   Salaorni, Sibeli ^a   Sarkis, Álvaro S ^b   Nagai, Maria A ^a  

^a Disciplina de Oncologia   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; CARBOXYPEPTIDASE D; CHONDROITIN POLYMERIZING FACTOR; CHROMOSOME 4 OPEN READING FRAME 8; COATOMER PROTEIN COMPLEX SUBUNIT BETA 2; DEVELOPMENT AND DIFFERENTIATION ENHANCING FACTOR 2; ENZYME; EPITHELIAL MEMBRANE PROTEIN 2; GENE PRODUCT; GLYCOPROTEIN GP 130; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MACROPHAGE ERYTHROBLAST ATTACHER; MALIC ENZYME 1; MICROFIBRILLAR ASSOCIATED PROTEIN 4; MITOCHONDRIAL CYTOCHROME B; MITOGEN ACTIVATED PROTEIN KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE 7; MYOSIN VI; NEUROPILIN AND TOLLOID LIKE 1 PROTEIN; SELENIUM BINDING PROTEIN 1; SPERM AUTOANTIGENIC PROTEIN 17; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR; TRANSLOCATION ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PROTEIN; UBIQUITIN FOLD MODIFIER 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL CYCLE REGULATION; CELL MIGRATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE ISOLATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HORMONE ACTION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR CLONING; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTIGENS, SURFACE; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GTPASE-ACTIVATING PROTEINS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RNA, MESSENGER; TIME FACTORS;

EID: 33646037046     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.09.012     Document Type: Article

References (57)

1. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Sem Oncol 26 (1999) 407-421
2. Latil A., and Lidereau R. Genetic aspects of prostate cancer. Virchows Arch 432 (1998) 389-406
3. Ruijter E., Van de Kaa C., Miller G., Ruiter D., Debruyne F., and Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocrine Rev 20 (1999) 22-45
4. Chang G.T.G., Steenbeek M., Schippers E., Blok L.J., van Weerden W.M., van Alewijk D.C.J.G., Eussen B.H.J., van Steenbrugge G.J., and Brinkmann A.O. A novel gene on human chromosome 2p24 is differentially expressed between androgen-dependent and androgen-independent prostate cancer cells. Eur J Cancer 37 (2001) 2129-2134
5. Velasco A.M., Gillis K.A., Li Y., Brown E.L., Sadler T.M., Achilleos M., Greenberger L.M., Frost P., Bai W., and Zhang Y. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145 (2004) 3913-3924
6. DePrimo S.E., Diehn M., Nelson H.B., Reiter R.E., Matese H., Fero M., Ribshirani R., Brown P.O., and Brooks J.D. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 3 (2002) 1-12
7. Xu L.L., Shanmugan N., Segawa T., Sesterhenn I.A., McLeod D.G., Moul J.W., and Srivastava S. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 66 (2000) 257-263
8. Xu L.L., Su Y.P., Labiche R., Segawa T., Shanmugam N., McLeod D.G., Moul J.W., and Srivastava S. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 92 (2001) 322-328
9. Waghray A., Schober M., Feroze F., Yao F., Virgin J., and Chen Y.Q. Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res 61 (2001) 4283-4286
10. Untergasser G., Koch H.B., Menssen A., and Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 62 (2002) 6255-6262
11. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., and Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
12. Luo J., Duggan D.J., Chen Y., Sauvageot J., Ewing C.M., Bittner M.L., Trent J.M., and Isaacs W.B. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61 (2001) 4683-4688
13. Nelson P.S., Clegg N., Arnold H., Ferguson C., Bonham M., White J., Hood L., and Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci 99 (2002) 11890-11895
14. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., and Gerald W.L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62 (2002) 4499-4506
15. Holzbeieirlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., and Gerald W.L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
16. Halvorsen O.J., Oyan A.M., Bo T.H., Olsen S., Rostad K., Kaukass S.A., Bakke A.M., Marzolf B., Dimitrov K., Stordrange L., Lin B., Jonassen I., Hood L., Akslen L.A., and Kalland K.H. Gene expression profiles in prostate cancer: association with subgroups and tumor differentiation. Int J Oncol 26 (2005) 329-336
17. Bouchal J., Baumforth K.R., Svachova M., Murray P.G., von Angerer E., and Kolar Z. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol 57 (2005) 83-92
18. Bussemakers M.J.G., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F.M., Schalken J.A., Debruyne F.M.J., Ru N., and Isaacs W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
19. Srikantan V., Zou Z., Petrovics G., Xu L., Augustus M., Davis L., Livezey J.R., Connell T., Sesterhenn I.A., Yoshino K., Buzard G.S., Mostofi F.K., McLeod D.G., Moul J.W., and Srivstava S. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci 97 (2000) 12216-12221
20. Benedit P., Paciucci R., Thomson T.M., Valeri M., Nadal M., Caceres C., de Torres I., Estivill X., Lozano J.J., Morote J., and Reventos J. PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology. Oncogene 20 (2001) 1455-1464
21. Chakrabarti R., Robles L.D., Gibson J., and Muroski M. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet 139 (2002) 115-125
22. Ishiguro H., Uemura H., Fujinami K., Ikeda N., Ohta S., and Kubota Y. 55Kda nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 105 (2003) 26-32
23. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
24. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., and Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173 (1990) 534-540
25. Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M.R., Parczyk K., and Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81 (1999) 242-251
26. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., and Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res 43 (1983) 1809-1818
27. Masiello D., Cheng S., Bubley G.J., Lu M.L., and Balk S.P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277 (2002) 26321-26326
28. Berrevoets C.A., Veldscholte J., and Mulder E. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Mol Biol 46 (1993) 731-736
29. Kuil C.W., Berrevoets C.A., and Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization: studies on the mechanism of antiandrogen action. J Biol Chem 270 (1995) 27569-27576
30. Jordan J.J., Nalón A.L., Al-Saleen T.I., Greenberg R.E., and Tricoli J.V. Loss of the short arm of the Y chromosome in human prostate carcinoma. Cancer Genet Cytogenet 124 (2001) 122-126
31. Goodarzi G., Mashimo T., Watabe M., Cuthbert A.P., Newbold R.F., Pai S.K., Hirota S., Hosobe S., Miura K., Bandyopadhyay S., Gross S.C., Balaji K.C., and Watabe K. Identification of tumor metastasis suppressor region on the short arm of human chromosome 20. Genes Chromosomes Cancer 32 (2001) 33-42
32. Hyytinen E.R., Saadut R., Chen C., Paull L., Koivisto P.A., Vessella R.L., Frierson Jr. H.F., and Dong J.T. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 34 (2002) 306-312
33. Strohmeyer D.M., Berger A.P., Moore II D.H., Bartsch G., Klocker H., Carroll P.R., Loening S.A., and Jensen R.H. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis. Prostate 59 (2004) 43-58
34. Matsuyama H., Pan Y., Yoshihiro S., Kudren D., Naito K., Bergerheim U.S., and Ekman P. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer. Prostate 54 (2003) 103-111
35. Ueda T., Komiya A., Suzuki H., Shimbo M., Sakamoto S., Imamoto T., Akakura K., Shiraishi T., and Ichikawa T. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer. Prostate 64 (2005) 265-271
36. von Knobloch R., Konrad L., Barth P.J., Brandt H., Wille S., Heidenreich A., Moll R., and Hofmann R. Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin Cancer Res 10 (2004) 1064-1073
37. Cher M.L., Bova G.S., Moore D.H., Small E.J., Carroll P.R., Pin S.S., Epstein J.I., Isaacs W.B., and Jensen R.H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56 (1996) 3091-3102
38. Alers J.C., Rochat J., Krijtenburg P.J., Hop W.C., Kranse R., Rosenberg C., Tanke H.J., Schroder F.H., and van Dekken H. Identification of genetic markers for prostatic cancer progression. Lab Invest 80 (2000) 931-942
39. Wullich B., Riedinger S., Brinck U., Stoeckle M., Kamradt J., Ketter R., and Jung V. Evidence for gains at 15q and 20q in brain metastases of prostate cancer. Cancer Genet Cytogenet 154 (2004) 119-123
40. Wen Y., Richardson R.T., Widgren E.E., and O'Rand M.G. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J 357 (2001) 25-31
41. Buchli R., De Jong A., and Robbins D.K. Genomic organization of an intron-containing sperm protein 17 gene (Sp17-1) and an intronless pseudogene (Sp17-2) in humans: a new model. Biochim Biophys Acta 1578 (2002) 29-42
42. Lim S.H., Wang Z., Chiriva-Internati M., and Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 97 (2001) 1508-1510
43. De Jong A., Buchli R., and Robbins D. characterization of sperm protein 17 in human somatic and neoplastic tissue. Cancer Letters 186 (2002) 201-209
44. Frayne J., and Hall L. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction 124 (2002) 767-774
45. Straughn Jr. J.M., Shaw D.R., Guerrero A., Bhoola S.M., Racelis A., Wang Z., Chriva-Internati M., Grizzle W.E., Alvarez R.D., Lim S.H., and Strong T.V. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 108 (2004) 805-811
46. Arora S., Matta A., Shukla N.K., Deo S.V., and Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 42 (2005) 97-108
47. Negrini M., Rasio D., Hampton G.M., Sabbioni S., Rattan S., Carter S.L., Rosenberg A.L., Schwartz G.F., Shiloh Y., Cavenne W.K., and Croce C.M. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res 55 (1995) 3003-3007
48. Martin E.S., Cesari R., Pentimalli F., Yoder K., Fishel R., Himelstein A.L., Martin S.E., Godwin A.K., Negrini M., and Croce C.M. The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci 100 (2003) 11517-11522
49. Rasio D., Negrini M., Manenti G., Dragani T.A., and Croce C.M. Loss of heterozygosity at chromosome 11q in lung adenocarcinomas: identification of three independent regions. Cancer Res 55 (1995) 3988-3991
50. Gabra H., Watson J.E., Taylor K.J., Mackay J., Leonard R.C., Steel C.M., Porteous D.J., and Smyth J.F. Definition and refinement of a region of loss of heterozygosity at 11q23-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 56 (1996) 950-954
51. Dahiya R., McCarville J., Lee C., Hu W., Kaur G., Carroll P., and Deng G. Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J Cancer 72 (1997) 283-288
52. Ishikawa K., Nagase T., Nakajima D., Seki N., Ohira M., Miyajima N., Tanaka A., Kotani H., Nomura N., and Ohara O. Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro. DNA Res 4 (1997) 307-313
53. Andreev J., Simon J.P., Sabatini D.D., Kam J., Plowman G., Randazzo P.A., and Schlessinger J. Identification of a new Pyk2 target protein with Arf-GAP activity. Mol Cel Biol 19 (1999) 2338-2350
54. Turner C.E., West K.A., and Brown M.C. Paxillin-ARF GAP signaling and the cytoskeleton. Curr Opin Cell Biol 13 (1999) 593-599
55. Uchida H., Kondo A., Yoshimura Y., Mazaki Y., and Sabe H. PAG3/Papα/KIAA0400, a GTPase-activating protein for ADP-ribosylation factor (ARF), regulates ARF6 in Fcγ receptor-mediated phagocytosis of macrophages. J Exp Med 193 (2001) 955-966
56. Mashimo T., Goodarzi G., Watabe M., Cuthbert A.P., Newbold R.F., Pai S.K., Hirota S., Hosobe K., Bandyopadhyay S., Gross S.C., and Watabe K. Localization of a novel tumor metastasis suppressor region on the short arm of human chromosome 2. Genes Chromosomes Cancer 28 (2000) 285-293
57. Kondo A., Hashimoto S., Yano H., Nagayama K., Mazaki Y., and Sabe H. A new paxillin-binding protein, PAG3/Papα/KIAA0400, bearing an ADP-ribosylation factor GTPase-activating protein activity, is involved in paxillin recruitment to focal adhesions and cell migration. Molecular Biol Cell 11 (2000) 1315-1327